Brain drug revivalAcadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street
The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.
https://www.biopharmadive.com/news/acadia-research-sales-update-nuplazid-daybue-pipeline/751745/
On Wednesday, Acadia also predicted the combined peak sales of Nuplazid and its other commercial medication, Daybue, will fall in the range of $1.5 billion to $2 billion. Approved in 2023, Daybue is used for patients with Rett syndrome, a rare, genetic disorder that impairs brain function and development.
Along with ACP-204, Acadia’s pipeline includes ACP-101, a drug for another rare, genetic, neurological disease called Prader-Willi Syndrome. High-level results from a Phase 3 experiment should arrive sometime between October and December. There’s also ACP-211, for major depression; ACP-711, for essential tremor; and ACP-2591, a “next-generation” approach to addressing Rett syndrome. Each of those three programs are in early-stage testing.
Brain drug revivalAcadia’s ‘very bullish’ sales forecast...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.13 |
Change
0.820(6.16%) |
Mkt cap ! $1.756B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.21 | $12.96 | $6.584M | 477.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 651 | $14.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.14 | 5028 | 2 |
View Market Depth
| Last trade - 14.33pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |